Monitoring of Anti-Malarial Drug resistance by real-time quantitative nucleic acid sequence-based amplification and the impact on TRANSmission of Plasmodium falciparum

Not Applicable

Completed

• Conditions: ncomplicated febrile malaria; Infections and Infestations; Malaria

• Registration Number: ISRCTN31291803
• Lead Sponsor: The Netherlands Foundation for the Advancement of Tropical Research (NWO-WOTRO) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2004-12-31
• Study Start: 2007-03-27
• Last Update Posted: 7 September 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 500

Inclusion Criteria

1. Age six months to ten years
2. Residents of research area, able to come for complete schedule of follow-up
3. Diagnosed with uncomplicated malaria, Plasmodium falciparum or P. falciparum and P. malariae double infection
4. Parasitaemia 1000 to 100,000 P. falciparum P/ul (Giemsa-stained blood smears counted against 200 White Blood Cells (WBC), negative result if 100 parasite negative microscopic fields)
5. Temperature more than 37.5°C and less than 39.5°C, or a history of fever in the previous 24 hours
6. No history of adverse reactions to Sulphadoxine-Pyrimethamine (SP) treatment
7. Understanding of the procedures of the study by parent or guardian and willing to participate (informed consent signed)

Exclusion Criteria

1. General danger signs of severe malaria or Haemoglobin (Hb) count more than 5 gm/dl
2. Severe malnutrition
3. Presence of diseases other than malaria causing febrile conditions
4. Unwilling to participate and sign informed consent forms

Study & Design

• Study Type: Interventional
• Study Design: Not specified